Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Historical BHVN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Multiple of Ten Bearish | Other | -0.25% | |
| Wide Bands | Range Expansion | -0.25% | |
| Overbought Stochastic | Strength | -0.25% | |
| Slingshot Bullish | Bullish Swing Setup | -7.39% | |
| Wide Bands | Range Expansion | -7.39% | |
| Overbought Stochastic | Strength | -7.39% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 4 hours ago |
| Down 2 % | about 6 hours ago |
| 60 Minute Opening Range Breakdown | about 6 hours ago |
| Possible NR7 | about 6 hours ago |
| 60 Minute Opening Range Breakout | about 9 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/10/2021
Biohaven Pharmaceutical Holding Company Ltd. Description
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Chemical Compounds Organic Compounds Neuroscience Degenerative Disease Degenerative Diseases Neurodegenerative Diseases Glutamate Riluzole
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 106.565 |
| 52 Week Low | 57.66 |
| Average Volume | 563,472 |
| 200-Day Moving Average | 79.36 |
| 50-Day Moving Average | 78.89 |
| 20-Day Moving Average | 88.52 |
| 10-Day Moving Average | 96.02 |
| Average True Range | 4.27 |
| ADX | 40.31 |
| +DI | 34.98 |
| -DI | 22.93 |
| Chandelier Exit (Long, 3 ATRs) | 93.75 |
| Chandelier Exit (Short, 3 ATRs) | 80.89 |
| Upper Bollinger Bands | 106.63 |
| Lower Bollinger Band | 70.41 |
| Percent B (%b) | 0.62 |
| BandWidth | 40.91 |
| MACD Line | 6.14 |
| MACD Signal Line | 5.81 |
| MACD Histogram | 0.3229 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 98.70 | ||||
| Resistance 3 (R3) | 98.64 | 96.67 | 97.74 | ||
| Resistance 2 (R2) | 96.67 | 95.22 | 96.70 | 97.42 | |
| Resistance 1 (R1) | 94.83 | 94.32 | 93.85 | 94.89 | 97.11 |
| Pivot Point | 92.86 | 92.86 | 92.37 | 92.89 | 92.86 |
| Support 1 (S1) | 91.02 | 91.41 | 90.04 | 91.08 | 88.85 |
| Support 2 (S2) | 89.05 | 90.51 | 89.08 | 88.54 | |
| Support 3 (S3) | 87.21 | 89.05 | 88.22 | ||
| Support 4 (S4) | 87.27 |
